MedTrace Logo

A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants

NCT07716241 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2026-07-21

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.

Conditions

Interventions

DRUG

HS-20136-2

Single-dose pen of HS-20136-2 injection solution

DRUG

Placebo

Single-dose of placebo

DRUG

HS-20136-2

multi-dose pen of HS-20136-2 injection solution

DRUG

placebo

multi-dose of placebo

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-22
Primary Completion
2027-05-14
Completion
2027-05-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07716241 on ClinicalTrials.gov